Welcome to our dedicated page for Neurogene news (Ticker: NGNE), a resource for investors and traders seeking the latest updates and insights on Neurogene stock.
Neurogene Inc. develops genetic medicines for rare neurological diseases, with recurring updates centered on NGN-401, its investigational AAV9 gene therapy for Rett syndrome. Company news covers the EXACT™ transgene regulation technology, intracerebroventricular delivery for CNS-targeted gene therapy, clinical data from NGN-401 studies, and regulatory designations granted by U.S., European, and U.K. agencies.
Other recurring Neurogene developments include financial results, corporate presentations, scientific conference participation, board and executive appointments, and equity inducement grants under Nasdaq Listing Rule 5635(c)(4). The company also identifies NGN-101 as a conventional gene therapy development candidate for CLN5 Batten disease.
Neurogene (Nasdaq: NGNE) announced an inducement equity grant approved by its Compensation Committee on November 4, 2025. The company granted non-qualified stock options to purchase 1,185 shares to one newly hired employee under the 2025 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price equal to the closing price on the grant date and vest over four years: 25% at the first anniversary of the vesting commencement date and the remaining 75% in equal installments every three months over the following 36 months, subject to continued employment.
Neurogene (NASDAQ: NGNE) completed discussions with the FDA on its Embolden™ registrational protocol and plans to initiate dosing in Q4 2025. The trial is expected to enroll across 13 sites to support rapid recruitment. The company highlighted new NHP data showing intracerebroventricular (ICV) delivery of NGN-401 yields superior transgene RNA expression in brain regions relevant to Rett syndrome versus intrathecal lumbar (IT-L) at clinically relevant doses, while showing comparable peripheral exposure. Neurogene holds RMAT and participates in the FDA START pilot. Two ESGCT posters were presented on October 9, 2025.
Neurogene (Nasdaq: NGNE) said company management will participate in the H.C. Wainwright Genetic Medicines Virtual Conference on Tuesday, October 14, 2025 at 7:00 a.m. ET.
Format includes a fireside chat plus investor meetings. A live webcast and a limited-time replay will be available from the Investor Relations events section on Neurogene’s website.
Neurogene (Nasdaq: NGNE) announced on October 3, 2025 that its Compensation Committee approved inducement grants of non-qualified stock options to purchase an aggregate of 9,390 shares for four new employees, effective October 1, 2025.
The grants were made under the company’s 2025 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The exercise price equals Neurogene’s closing stock price on the grant date. Vesting is over four years: 25% at the first anniversary of the vesting commencement date, then equal installments every three months over the following 36 months, subject to continued employment.
Neurogene (Nasdaq: NGNE), a clinical-stage company focused on genetic medicines for rare neurological diseases, has announced the approval of inducement grants for new employees. The Compensation Committee approved non-qualified stock options to purchase 47,040 shares of common stock for six new employees on September 3, 2025.
The grants, made under the company's 2025 Inducement Plan, will vest over four years with 25% vesting on the first anniversary and the remainder vesting quarterly over the following 36 months. The exercise price equals the closing price of Neurogene's stock on the grant date. These grants comply with Nasdaq Listing Rule 5635(c)(4) as material inducements for employment.
Neurogene (Nasdaq: NGNE) reported Q2 2025 financial results and provided updates on its NGN-401 gene therapy program for Rett syndrome. The company has completed dosing in its Phase 1/2 trial and received FDA agreement on key elements of the Embolden™ registrational trial, with trial initiation activities already underway.
Financial highlights include a strong cash position of $274.5 million, providing runway into early 2028. Q2 2025 saw a net loss of $22.0 million, with R&D expenses of $19.4 million and G&A expenses of $6.7 million. The company plans to report updated clinical efficacy and safety data from the Phase 1/2 trial in H2 2025.
Neurogene (Nasdaq: NGNE), a clinical-stage company focused on genetic medicines for rare neurological diseases, has announced inducement grants for new employees. The Compensation Committee approved non-qualified stock options to purchase 27,480 shares of common stock for seven new employees on August 6, 2025.
The stock options, granted under the company's 2025 Inducement Plan, will vest over four years with 25% vesting on the first anniversary and the remaining vesting quarterly over 36 months. The exercise price equals the closing price of Neurogene's stock on the grant date. These grants comply with Nasdaq Listing Rule 5635(c)(4) as inducement material for employment.
Neurogene (Nasdaq: NGNE), a clinical-stage company focused on genetic medicines for rare neurological diseases, has announced inducement grants for two new employees. The Compensation Committee approved non-qualified stock options to purchase 4,290 shares of common stock on July 3, 2025.
The stock options, granted under the company's 2025 Inducement Plan, will vest over a four-year period, with 25% vesting after the first year and the remainder vesting quarterly over the following 36 months. The exercise price is set at the closing price of Neurogene's stock on the grant date. These grants comply with Nasdaq Listing Rule 5635(c)(4) and serve as employment inducements.
Neurogene (NASDAQ: NGNE) has announced key details of its Embolden™ registrational trial for NGN-401, a gene therapy treatment for Rett syndrome in females aged 3 years and older. The company has received FDA written agreement on critical aspects of the trial design.
The registrational trial will be a single-arm, open-label study with a proposed enrollment of 18 participants. The primary endpoint combines improvement in Clinical Global Impression-Improvement (CGI-I) scale and gain of developmental milestone/skill, compared to baseline. The study will use the 1E15 vector genomes (vg) dose.
In the Phase 1/2 trial, 10 participants have received treatment at the 1E15 vg dose, with no evidence of HLH/hyperinflammatory syndrome. Early data from the first four participants showed promising results, with participants collectively achieving 23 developmental milestones/skills across multiple domains.
The company reports a strong financial position with $292.6 million in cash and investments as of March 31, 2025, extending their runway into early 2028. Updated clinical efficacy and safety data are expected in the second half of 2025.